ViewsML, a pioneer in AI-powered virtual immunohistochemistry (IHC) staining, and iProcess Global Research, a leading provider of biospecimen and clinical research solutions, announced a strategic partnership on August 18, 2025, to expand access to ViewsML's virtual biomarker technology. The collaboration will bring cutting-edge digital pathology tools to iProcess's extensive network of research institutions, diagnostic labs, and pharmaceutical partners.
Revolutionary Virtual Staining Technology
Under the partnership agreement, iProcess will offer ViewsML's virtual IHC technology to its customers, enabling access to digital pathology tools that eliminate the need for physical biomarker staining. The technology dramatically accelerates turnaround times, preserves rare tissue samples, and enables multiplex analysis in silico.
"We're excited to partner with iProcess to bring the benefits of our virtual IHC platform to their customers," said Keith Jalbert, Chief Commercial Officer of ViewsML. "iProcess has an exceptional reputation for biospecimen access, histopathology services, and operational scale. By integrating our AI-powered virtual staining into their offerings, researchers and drug developers will be able to generate high-resolution, quantitative biomarker insights in seconds—not days—whilst increasing the value of every tissue sample."
Platform Capabilities and Workflow Integration
ViewsML's platform enables researchers to predict biomarker expression at the per-cell level using only a single H&E image, fitting seamlessly into existing pathology workflows. The technology supports applications ranging from research through diagnostics, with virtual panels covering a wide range of biomarkers. The platform virtualizes antibodies and immunostaining to predict biomarker expression both spatially and quantitatively, reducing a process that traditionally takes days to mere minutes.
For iProcess, the partnership enhances its digital pathology capabilities and unlocks new service offerings for pharmaceutical clients and academic partners seeking to maximize sample utility and accelerate biomarker-driven decisions.
Addressing Market Demand
"We see ViewsML's virtual IHC as a game-changer for the way tissue samples are characterized and utilized," said Asker Ahmed, Director and Founder at iProcess. "Our clients are demanding faster, more scalable, and cost-effective biomarker analysis—especially in early drug discovery and high-throughput settings. With ViewsML as a partner, we can now offer AI-powered tissue interrogation with unmatched speed, precision, and tissue preservation. We're thrilled to bring this innovation to our clients."
The partnership addresses the growing need for efficient biomarker analysis in pharmaceutical research and development, where tissue preservation and rapid analysis are critical for advancing precision medicine initiatives. ViewsML's technology transforms precision medicine and diagnostics through virtual biomarkers, while iProcess specializes in human biospecimen access, clinical research support, and laboratory services for the pharmaceutical, biotech, and diagnostics industries.
